High-content microscopy reveals a morphological signature of bortezomib resistance
eLife · 2023
DOI: 10.7554/elife.91362 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Megan E Kelley und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Chemistry and Cell Biology, The Rockefeller University, New York City, United States. Hauptthemen laut MEDLINE: Microscopy, Antineoplastic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, Starr Cancer Consortium.
Abstract (Originalsprache)
Drug resistance is a challenge in anticancer therapy. In many cases, cancers can be resistant to the drug prior to exposure, that is, possess intrinsic drug resistance. However, we lack target-independent methods to anticipate resistance in cancer cell lines or characterize intrinsic drug resistance without a priori knowledge of its cause. We hypothesized that cell morphology could provide an unbiased readout of drug resistance. To test this hypothesis, we used HCT116 cells, a mismatch repair-deficient cancer cell line, to isolate clones that were resistant or sensitive to bortezomib, a well-characterized proteasome inhibitor and anticancer drug to which many cancer cells possess intrinsic resistance. We then expanded these clones and measured high-dimensional single-cell morphology profiles using Cell Painting, a high-content microscopy assay. Our imaging- and computation-based profiling pipeline identified morphological features that differed between resistant and sensitive cells. We used these features to generate a morphological signature of bortezomib resistance. We then employed this morphological signature to analyze a set of HCT116 clones (five resistant and five sensitive) that had not been included in the signature training dataset, and correctly predicted sensitivity to bortezomib in seven cases, in the absence of drug treatment. This signature predicted bortezomib resistance better than resistance to other drugs targeting the ubiquitin-proteasome system, indicating specificity for mechanisms of resistance to bortezomib. Our results establish a proof-of-concept framework for the unbiased analysis of drug resistance using high-content microscopy of cancer cells, in the absence of drug treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Chemistry and Cell Biology, The Rockefeller University, New York City, United States.
- Imaging Platform, Broad Institute, Cambridge, United States.
- Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, United States.
ORCID-Profile: Megan E Kelley, Adi Y Berman, David R Stirling, Beth A Cimini, Yu Han, Shantanu Singh, Anne E Carpenter, Tarun M Kapoor, Gregory P Way
Förderung
- NIGMS NIH HHS
- NIH HHS
- Starr Cancer Consortium
- National Institutes of Health
- National Science Foundation
Zitieren
APA
Kelley, M. E., Berman, A. Y., Stirling, D. R., Cimini, B. A., Han, Y., Singh, S., Carpenter, A. E., Kapoor, T. M., & Way, G. P. (2023). High-content microscopy reveals a morphological signature of bortezomib resistance. eLife. https://doi.org/10.7554/elife.91362
Vancouver
Kelley ME, Berman AY, Stirling DR, Cimini BA, Han Y, Singh S, et al. High-content microscopy reveals a morphological signature of bortezomib resistance. eLife. 2023. doi:10.7554/elife.91362
BibTeX
@article{Kelley2023,
author = {Kelley, Megan E and Berman, Adi Y and Stirling, David R and Cimini, Beth A and Han, Yu and Singh, Shantanu and Carpenter, Anne E and Kapoor, Tarun M and Way, Gregory P},
title = {High-content microscopy reveals a morphological signature of bortezomib resistance},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.91362}
}
EUVIMED